Dr. Torbjörn Bjerke

Biography

Torbjorn Bjerke MD, contributes valuable skills and great expertise in the treatment of allergies and drug development as a result of his vast experience as CEO for Biolipox, Orexo and Karolinska Development. Dr Bjerke has more than 25 years of experience from the pharmaceutical industry also including Executive Vice President of the Research and Development at ALK-Abelló and prior to that occupied positions as Director of Inflammation Pharmacology at AstraZeneca and visiting scientist at Genentech Inc. Torbjorn also co-founded Action Pharma (sold to Abbott) and most recently TXP Pharma.

Research Interest

pharmaceutical industry Management